Ignite Creation Date:
2025-12-25 @ 3:38 AM
Ignite Modification Date:
2025-12-26 @ 2:22 AM
Study NCT ID:
NCT07287202
Status:
NOT_YET_RECRUITING
Last Update Posted:
2025-12-23
First Post:
2025-12-11
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Safety, Tolerability, and Pharmacokinetics of SVG103 (Paxalisib) in Focal Cortical Dysplasia Type II (FCD-II), Tuberous Sclerosis Complex (TSC) or Hemimegalencephaly (HME)
Sponsor:
SoVarGen Co., Ltd.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2026-03
Start Date Type:
ESTIMATED
Primary Completion Date:
2026-12
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-06
Completion Date Type:
ESTIMATED
First Submit Date:
2025-12-11
First Submit QC Date:
None
Study First Post Date:
2025-12-17
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-12-22
Last Update Post Date:
2025-12-23
Last Update Post Date Type:
ESTIMATED